Los Angeles Capital Management LLC Boosts Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Los Angeles Capital Management LLC grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,555 shares of the company’s stock after buying an additional 637 shares during the period. Los Angeles Capital Management LLC’s holdings in IDEXX Laboratories were worth $4,079,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in IDXX. Valley National Advisers Inc. lifted its position in IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after buying an additional 22 shares in the last quarter. DSM Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $33,000. Private Wealth Management Group LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $34,000. Venturi Wealth Management LLC boosted its holdings in IDEXX Laboratories by 226.3% in the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after acquiring an additional 43 shares during the period. Finally, Geo Capital Gestora de Recursos Ltd purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $28,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction on Friday, May 17th. The stock was sold at an average price of $540.80, for a total value of $108,160.00. Following the sale, the director now directly owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 1.5 %

IDEXX Laboratories stock opened at $495.96 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The firm’s 50-day moving average is $500.84 and its 200-day moving average is $528.32. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The company has a market cap of $40.96 billion, a P/E ratio of 48.01, a PEG ratio of 4.11 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The firm had revenue of $964.10 million for the quarter, compared to analysts’ expectations of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on IDXX shares. Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Barclays reduced their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $580.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.